RCM macrocyclization made practical: an efficient synthesis of HCV protease inhibitor BILN 2061
Chutian Shu1, Xingzhong Zeng, Ming-Hong Hao
1Department of Chemical Development, Boehringer Ingelheim Pharmaceuticals, 900 Ridgebury Road, Ridgefield Connecticut 06877, USA. chutian.shu@boehringer-ingelheim.com
Abstract:
We report here that dramatic improvement of the key RCM reaction in the synthesis of HCV protease inhibitor BILN2061 can be achieved by N-substitution of the diene substrate with an electron-withdrawing group. Mechanistic studies using 1H NMR spectroscopy showed an unprecedented switch of the initiation sites and the correlation between such switch and the results of RCM, from the unmodified to the modified substrates. We also provided theoretical evidence that such modification may also increase the thermodynamic preference of the macrocyclic product over the diene substrate.
More Related Videos
Related Concept Videos
Antiviral Nucleoside Inhibitors
Cyclohexenones via Michael Addition and Aldol Condensation: The Robinson Annulation


